Modified HAdV-D10 Adenovirus for Targeted Oncolytic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic adenovirus therapies, such as those based on HAdV-C5, face limitations due to high pre-existing immunity, hepatotoxicity, and reduced efficacy due to interactions with human coagulation factor X and ubiquitous receptor distribution, limiting their cancer-targeting specificity and effectiveness.
Innovation Solution
A modified D species human adenovirus, HAdV-D10, is engineered with a 20 amino acid peptide (A20) for selective affinity to αvβ6 integrin, reducing binding to coxsackievirus and adenovirus receptor (CAR) and avoiding interaction with human coagulation factor X, thereby enhancing tumor specificity and evading neutralization in human serum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HAdV-C5 is used as an oncolytic virus, then it can infect and replicate in tumor cells, but it binds to CAR which is ubiquitously expressed and can be downregulated in certain cancers, limiting cancer-targeting specificity
Solution Approach 1:
The patent applies local quality by modifying the fiber knob protein of HAdV-D10 to specifically target αvβ6 integrin, which is locally upregulated in certain cancer types. This creates a localized targeting mechanism that distinguishes tumor cells from normal cells, resolving the contradiction between achieving cancer-specific targeting and avoiding ubiquitous receptor binding.
Solution Approach 2:
The patent changes the binding parameter of the adenovirus by engineering the fiber knob protein to recognize αvβ6 integrin instead of CAR. This parameter change in receptor specificity allows the virus to target cancers that overexpress αvβ6 integrin while avoiding the limitations of CAR-based targeting, thereby improving cancer-targeting specificity.
2Reliability
If HAdV-C5 is used for transduction, then it can deliver therapeutic genes to cells, but it interacts with human coagulation factor X in serum, mediating transduction to the liver and causing hepatotoxicity
Solution Approach 1:
The patent applies the taking out principle by selecting HAdV-D10, which naturally lacks the ability to bind human coagulation factor X. This extracts the harmful liver-targeting property from the adenovirus system while retaining the desired oncolytic capability, thereby eliminating hepatotoxicity without sacrificing therapeutic efficacy.
Solution Approach 2:
The patent converts the potential harm of liver transduction into a benefit by using a virus serotype (HAdV-D10) that naturally avoids FX binding. This transforms what would be a harmful off-target effect into a favorable selective advantage, allowing the virus to spare the liver while maintaining anti-tumor activity.
3Reliability
If HAdV-C5 based oncolytic virotherapies are systemically delivered, then they can reach tumor cells, but pre-existing neutralizing antibodies in the population rapidly inactivate the therapeutic vectors, reducing clinical efficacy
Solution Approach 1:
The patent applies the inversion principle by switching from a common adenovirus serotype (HAdV-C5) to a rare serotype (HAdV-D10) that is unlikely to have pre-existing neutralizing antibodies. This inverts the approach of dealing with immunity by not encountering it in the first place, thereby preserving clinical efficacy of systemically delivered oncolytic virotherapy.
4Reliability
If the A20 peptide is inserted into HAdV-D10 to target αvβ6 integrin, then tumor selectivity is enhanced, but the virus structure is modified requiring optimization for optimal delivery
Solution Approach 1:
The patent applies preliminary action by pre-optimizing the HAdV-D10 virus structure and A20 peptide insertion to achieve optimal delivery characteristics. This preliminary optimization ensures that the modified virus maintains proper assembly, stability, and transduction efficiency while gaining enhanced tumor selectivity, thereby managing structural complexity before clinical application.
Data Source
AI summary
The invention concerns a modified low seroprevalence adenovirus: a pharmaceutical composition comprising same; and a method of treating cancer using same.